Form 4: Arcus Biosciences President Juan C. Jaen Sells Shares
SEC Form 4
Arcus Biosciences' President, Juan C. Jaen, sold shares of common stock on February 26 and 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Juan C. Jaen, President of Arcus Biosciences, sold shares of the company's common stock on February 26 and 27, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on August 8, 2023.
- On February 26, 2024, 3,900 shares were sold at a weighted average price of $20.06, with prices ranging from $20.01 to $20.13.
- On February 27, 2024, 23,132 shares were sold at a weighted average price of $20.10, with prices ranging from $20.00 to $20.29.
- Following these transactions, Jaen directly owns 341,475 shares and indirectly owns 1,188,233 shares through a trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider selling activity. The sentiment is neutral as it simply reports transactions without expressing any opinion on the company's performance or future prospects.
Industry Context
Insider sales are a common occurrence in publicly traded companies and are often related to personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information.
Stakeholder Impact
- Shareholders may react to the insider selling activity, although the presence of a 10b5-1 trading plan mitigates concerns about opportunistic trading.
Key Dates
| Date | Description |
|---|---|
| 2023-08-08 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-02-26 | Date of first reported transaction: sale of 3,900 shares. |
| 2024-02-27 | Date of second reported transaction: sale of 23,132 shares. |
| 2024-02-28 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.